Filing Flows › Atara Biotherapeutics (ATRA) › Q3 2025
Atara Biotherapeutics (ATRA) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 12, 2025
Atara Biotherapeutics (ATRA) reported revenue of $3.5M for the third quarter 2025 (Q3 2025), -91% from a year earlier and -80% from the quarter before. Operating margin was -103.5%, net loss $4.3M (124.6% of revenue).
Atara Biotherapeutics, Q3 2025: revenue $3.5M (-91% year over year), operating margin -103.5%, net loss $4.3M, operating cash flow −$9.8M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.5M | -80% | -91% |
| Operating profit | −$3.6M | -212% | — |
| Net earnings | −$4.3M | -280% | — |
| Operating cash flow | −$9.8M | — | — |
What changed
Revenue was $3.5M in Q3 2025, down 91% year over year and down 80% from the previous quarter.
Operating costs exceeded revenue by $3.6M, an operating margin of -103.5%. Total costs fell 89% while revenue fell 91%. The quarter ended with a net loss of $4.3M, after a profit of $2.4M the previous quarter.
Operating cash flow was −$9.8M. Non-cash charges added back $36K of depreciation and amortization and $1.2M of share-based compensation. Working capital and other items used $6.7M.
Questions
What was Atara Biotherapeutics' revenue in the third quarter 2025?
Atara Biotherapeutics (ATRA) reported revenue of $3.5M for the third quarter 2025 (Q3 2025), -91% from a year earlier and -80% from the quarter before.
Was Atara Biotherapeutics profitable in the third quarter 2025?
Operating loss was $3.6M (-103.5% of revenue) and net loss $4.3M.